Skip to content
20-F

Annual Report (Foreign)

Virax Biolabs Group Limited VRAX

0000950170-25-093260

← back to feed
Filed
Jul 2, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Mar 31, 2025 3.73M sh
Shares Diluted FY 2025 · Mar 31, 2024 2.01M sh
Shares Diluted restated FY 2025 · Mar 31, 2023 1.06M sh
Shares Outstanding FY 2025 · Mar 31, 2025 4.34M sh
Operating Cash Flow FY 2025 · Mar 31, 2025 −$4.56M
Operating Cash Flow FY 2025 · Mar 31, 2024 −$6.25M
Operating Cash Flow FY 2025 · Mar 31, 2023 −$4.18M
Cash And Equivalents FY 2025 · Mar 31, 2025 $4.23M
Cash And Equivalents FY 2025 · Mar 31, 2024 $3.59M
Cash And Equivalents FY 2025 · Mar 31, 2023 $9.35M
Cash And Equivalents FY 2025 · Mar 31, 2022 $21.76K
Stockholders Equity FY 2025 · Mar 31, 2025 $5.46M
Stockholders Equity FY 2025 · Mar 31, 2024 $5.14M
Stockholders Equity FY 2025 · Mar 31, 2023 $8.9M
Stockholders Equity restated FY 2025 · Mar 31, 2022 −$1.2M
Current Liabilities FY 2025 · Mar 31, 2025 $673.21K
Current Liabilities FY 2025 · Mar 31, 2024 $168.85K
Total Liabilities FY 2025 · Mar 31, 2025 $964.75K
Total Liabilities FY 2025 · Mar 31, 2024 $345.19K
Current Assets FY 2025 · Mar 31, 2025 $4.89M
Current Assets FY 2025 · Mar 31, 2024 $4.38M
Total Assets FY 2025 · Mar 31, 2025 $6.43M
Total Assets FY 2025 · Mar 31, 2024 $5.48M
Eps Diluted FY 2025 · Mar 31, 2025 −$1.62
Eps Diluted FY 2025 · Mar 31, 2024 −$3.36
Eps Diluted restated FY 2025 · Mar 31, 2023 −$5.13
Eps Basic FY 2025 · Mar 31, 2025 −$1.62
Eps Basic FY 2025 · Mar 31, 2024 −$3.36
Eps Basic restated FY 2025 · Mar 31, 2023 −$5.13
Rd Expense FY 2025 · Mar 31, 2025 $1.78M
Rd Expense FY 2025 · Mar 31, 2024 $1.56M
Rd Expense restated FY 2025 · Mar 31, 2023 $2.18M
Net Income FY 2025 · Mar 31, 2025 −$6.07M
Net Income FY 2025 · Mar 31, 2024 −$6.74M
Net Income FY 2025 · Mar 31, 2023 −$5.46M
Operating Income FY 2025 · Mar 31, 2025 −$6.16M
Operating Income FY 2025 · Mar 31, 2024 −$6.5M
Operating Income FY 2025 · Mar 31, 2023 −$5.73M
Gross Profit FY 2025 · Mar 31, 2025 −$53.07K
Gross Profit FY 2025 · Mar 31, 2024 $50.59K
Gross Profit FY 2025 · Mar 31, 2023 −$1.37K
Cost Of Revenue FY 2025 · Mar 31, 2025 $59.4K
Cost Of Revenue FY 2025 · Mar 31, 2024 $105.83K
Cost Of Revenue FY 2025 · Mar 31, 2023 $9.93K